




Clinical Antiviral Sponsors and Developers

Clinical Antiviral Landscape: Sponsors & Developers*

- The biopharmaceutical industry (both large and small companies) represents **67 (89.3%)** of the global antiviral clinical developers (**75**).
 - Academia **7.3%**
 - Government groups **2.4%**
 - Contract Research Organizations (CRO) **<1%**
- For the **39** Promising and Watch & Wait clinical compound/indications:
 - The countries most represented by developers/sponsors are the United States (**46.6%**) and China (**36.8%**). Others include:
 - Australia, Hong Kong, Japan, Russia, Switzerland, Taiwan, each at **2.6%**
 - Belgium at **1.3%**
 - The majority (**63.2%**) of developers/sponsors are located in countries with high-income economies.
 - The remainder are located in China which has an upper-middle income economy class.

*As of December 18, 2024; Includes clinical compounds categorized as Approved/Investigational Antivirals-Indication Expansions, Promising, and Watch & Wait.


Clinical Antiviral Compound/Indications by Sponsor/Developer Type*



- ▶ Biotech/Pharma account for the majority of sponsors/developers for clinical phase compound/indications.
- ▶ Similarly, they account for the majority of preclinical exploratory evaluations with approved or investigational clinical compounds for a virus indication other than approved or under investigation in clinical trials.

*As of December 18, 2024; Includes clinical compounds categorized as Approved/Investigational Antivirals-Indication Expansions, Promising, and Watch & Wait. CRO: contract research organization.


Clinical Antiviral Compound/Indications by Sponsor/Developer WHO-Region* (N=75)



► The Americas and Western Pacific regions are primarily driven by the United States and China.

*As of December 18, 2024; Includes clinical compounds categorized as Approved/Investigational Antivirals-Indication Expansions, Promising, and Watch & Wait.

Clinical Antiviral Compound/Indications* by Country and World Bank Economy Class** (N=75)



- ▶ The majority (**78.5%**) of sponsors/developers of Indication Expansion, Promising and Watch & Wait clinical antiviral compound/indications are located in countries with high-income economies.
 - ▶ The remainder are those with upper-middle (**19.1%**) and lower-middle (**2.4%**) income economies.
- ▶ The United States (HI) and China (UMI) have the most representation.

*As of December 18, 2024; Includes clinical compounds categorized as Approved/Investigational Antivirals-Indication Expansions, Promising, and Watch & Wait.

**[World Bank country classifications by income level for 2024-2025](#); LMI: lower-middle income; UMI: upper-middle income; HI: high-income.

Disclaimer

The INTREPID Alliance is a not-for-profit consortium of innovative biopharmaceutical companies committed to accelerating antiviral research, aiming to ensure that we have a stronger pipeline and are better prepared for future pandemics.

As part of our efforts, the INTREPID Alliance maintains and publishes a centralized list of promising investigational candidate compounds, with the purpose of knowledge-sharing and to support better pandemic preparedness. These compounds have been selected based on objective, scientific criteria, using publicly available sources, and at arm's length from commercial influence of our member companies. See criteria listed in the report “Antiviral Clinical Development Landscape and Promising Clinical Compounds.” The designation of certain compounds as promising is based upon currently available information, and exclusively upon an assessment against these criteria.

“Promising” is not a promotional claim. Candidate compounds have not been assessed by regulatory authorities to be safe and efficacious for the treatment of disease in humans. Our content is designed to be factual, informative, and non-commercial. It is not designed or intended to advertise or promote any pharmaceutical product or therapy or to advance the commercial interests of any company.